Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention (PCSK9-DUO)
PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention
This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
Lowering low-density lipoprotein cholesterol (LDL-C) is essential to reduce the risk of cardiovascular events. While PCSK9 inhibitors are effective, many patients treated with a single agent do not reach recommended LDL-C targets, especially those who cannot take statins.
Inclisiran and alirocumab reduce LDL-C through different mechanisms. Inclisiran decreases the production of PCSK9 in the liver, while alirocumab binds circulating PCSK9 in the blood. Combining these therapies may lead to a greater reduction in LDL-C levels.
In this randomized, open-label clinical trial, approximately 60 patients in secondary prevention will be assigned to one of three groups: inclisiran alone, alirocumab alone, or a combination of both treatments. Patients will be followed for 9 months with regular clinical and laboratory assessments.
The main goal of the study is to determine whether combination therapy leads to greater LDL-C reduction compared to each treatment alone. Secondary objectives include assessing the proportion of patients achieving target LDL-C levels and evaluating treatment safety and tolerability.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a major modifiable risk factor. Despite the availability of effective lipid-lowering therapies, a substantial proportion of high-risk patients fail to achieve recommended LDL-C targets, particularly those with statin intolerance.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating LDL receptor degradation and plasma LDL-C levels. Pharmacological inhibition of PCSK9 has emerged as an effective strategy to reduce LDL-C. Two distinct therapeutic approaches are currently available: monoclonal antibodies (such as alirocumab), which neutralize circulating PCSK9, and small interfering RNA therapies (such as inclisiran), which reduce hepatic production of PCSK9.
Although both approaches have demonstrated efficacy, real-world data suggest that monotherapy may not be sufficient for many high-risk patients. The combination of these two mechanisms may provide additive or synergistic effects, leading to more profound LDL-C reduction.
This study is designed as a prospective, randomized, open-label, monocentric clinical trial. Approximately 60 adult patients in secondary prevention with statin intolerance and elevated LDL-C (2.5-5.0 mmol/L) will be enrolled. Participants will be randomized in a 1:1:1 ratio to receive inclisiran, alirocumab, or a combination of both therapies.
Inclisiran will be administered subcutaneously at baseline and at 3 months. Alirocumab will be administered subcutaneously at a dose of 300 mg every 4 weeks in a supervised clinical setting. Patients will be followed for 9 months, with study visits at baseline, 1 month, 3 months, 6 months, and 9 months.
The primary endpoint is the percentage change in LDL-C from baseline at 3 and 9 months. Secondary endpoints include the proportion of patients achieving guideline-recommended LDL-C targets, changes in other lipid parameters, and safety outcomes including adverse events and treatment tolerability.
This study aims to provide proof-of-concept evidence on the effectiveness and safety of dual PCSK9 inhibition using complementary mechanisms, with potential implications for improving lipid management in high-risk, statin-intolerant patients.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Zlatko Fras, MD, PhD
- Numéro de téléphone: +386 1 522 25 62
- E-mail: zlatko.fras@kclj.si
Sauvegarde des contacts de l'étude
- Nom: Jan Kafol, MD
- E-mail: jan.kafol@kclj.si
Lieux d'étude
-
-
-
Ljubljana, Slovénie, 1000
- Recrutement
- University Medical Centre Ljubljana
-
Contact:
- Zlatko Fras, MD, PhD
- Numéro de téléphone: +386 1 522 25 62
- E-mail: zlatko.fras@kclj.si
-
Contact:
- Jan Kafol, MD
- E-mail: jan.kafol@kclj.si
-
Chercheur principal:
- Jan Kafol, MD
-
Sous-enquêteur:
- Zlatko Fras, MD, PhD
-
Sous-enquêteur:
- Borut Jug, MD, PhD
-
Sous-enquêteur:
- Marko Novakovic, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged ≥18 years
- Established atherosclerotic cardiovascular disease (secondary prevention), defined as prior cardiovascular events or imaging-confirmed atherosclerosis (e.g., coronary artery disease on angiography or CT, carotid plaque on ultrasound, or peripheral arterial disease).
- Eligible for PCSK9 inhibitor therapy according to national clinical criteria
- Fasting LDL cholesterol ≥2.5 mmol/L and ≤5.0 mmol/L at screening
- Documented statin intolerance or contraindication to statin therapy
- On stable background lipid-lowering therapy (including ezetimibe if applicable) for at least 4 weeks prior to enrollment
- Able and willing to provide written informed consent
Exclusion Criteria:
- Eligibility for PCSK9 inhibitor therapy solely based on elevated lipoprotein(a) >1000 mg/L with LDL-C below inclusion threshold
- Prior use of any PCSK9 inhibitor (alirocumab, evolocumab or inclisiran) before enrollment
- Planned initiation or modification of lipid-lowering therapy during the study period
- Known homozygous familial hypercholesterolemia
- Active liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3× upper limit of normal
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Active malignancy or life expectancy <1 year
- Pregnancy, breastfeeding, or women of childbearing potential not using effective contraception
- Known hypersensitivity to inclisiran, alirocumab, or any of their excipients
- Participation in another interventional clinical trial within 30 days prior to enrollment
- Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Inclisiran
Participants receive inclisiran 284 mg administered subcutaneously at baseline and at 3 months.
Patients will be followed for 9 months with scheduled clinical and laboratory assessments.
|
Participants receive inclisiran 284 mg administered subcutaneously at baseline (Day 0) and at Month 3.
|
|
Expérimental: Alirocumab
Participants receive alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
Patients will be followed with regular clinical and laboratory assessments.
|
Participants receive alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
|
|
Expérimental: Inclisiran Plus Alirocumab
Participants receive inclisiran 284 mg administered subcutaneously at baseline and at 3 months, in combination with alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
Patients will be followed with scheduled clinical and laboratory assessments.
|
Participants receive inclisiran 284 mg administered subcutaneously at baseline (Day 0) and at Month 3.
Participants receive alirocumab 300 mg administered subcutaneously every four weeks in a supervised clinical setting for 9 months.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent Change in LDL-C From Baseline
Délai: 3 months and 9 months
|
Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline at 3 months and 9 months, comparing inclisiran, alirocumab, and combination therapy.
|
3 months and 9 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Trajectory of Percent Change in LDL-C From Baseline
Délai: 1, 3, 6, and 9 months
|
Percent change in LDL-C from baseline at each scheduled follow-up visit to assess early response and durability of treatment effect.
|
1, 3, 6, and 9 months
|
|
Proportion of Participants Achieving LDL-C <1.4 mmol/L
Délai: 1, 3, 6, and 9 months
|
Proportion of participants achieving LDL-C below 1.4 mmol/L at each scheduled follow-up visit.
|
1, 3, 6, and 9 months
|
|
Change in Apolipoprotein B From Baseline
Délai: 1, 3, 6, and 9 months
|
Absolute and percent change in apolipoprotein B from baseline.
|
1, 3, 6, and 9 months
|
|
Change in Non-HDL Cholesterol From Baseline
Délai: 1, 3, 6, and 9 months
|
Absolute and percent change in non-HDL cholesterol from baseline.
|
1, 3, 6, and 9 months
|
|
Change in Lipoprotein(a) From Baseline
Délai: 1, 3, 6, and 9 months
|
Absolute and percent change in lipoprotein(a) from baseline.
|
1, 3, 6, and 9 months
|
|
Incidence of Adverse Events
Délai: Up to 9 months
|
Number and proportion of participants experiencing any adverse event during the study.
|
Up to 9 months
|
|
Treatment Discontinuation Due to Adverse Events
Délai: Up to 9 months
|
Proportion of participants who discontinue assigned study treatment because of adverse events.
|
Up to 9 months
|
|
Change in Circulating PCSK9 Concentration From Baseline
Délai: 1, 3, 6, and 9 months
|
Absolute and percent change in circulating PCSK9 concentration to assess pharmacodynamic effects of treatment.
|
1, 3, 6, and 9 months
|
|
Change From Baseline in LDL-C Concentration
Délai: 1, 3, 6, and 9 months
|
Absolute change in LDL-C concentration compared with baseline at each scheduled follow-up visit.
|
1, 3, 6, and 9 months
|
|
Change From Baseline in Total Cholesterol, HDL Cholesterol, and Triglyceride Concentrations
Délai: 1, 3, 6, and 9 months
|
Change in serum total cholesterol, HDL cholesterol, and triglyceride concentrations compared with baseline values.
|
1, 3, 6, and 9 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Injection-Site Reactions
Délai: Up to 9 months
|
Number and proportion of participants experiencing injection-site reactions.
|
Up to 9 months
|
|
Treatment Adherence
Délai: Up to 9 months
|
Adherence to assigned therapy assessed by documented administration of inclisiran and alirocumab.
|
Up to 9 months
|
|
Major Adverse Cardiovascular Events
Délai: Up to 9 months
|
Exploratory assessment of cardiovascular death, myocardial infarction, stroke, urgent coronary revascularization, or hospitalization for unstable angina.
|
Up to 9 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Zlatko Fras, MD, PhD, University Medical Centre Ljubljana
- Chercheur principal: Jan Kafol, MD, University Medical Centre Ljubljana
Publications et liens utiles
Publications générales
- Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.
- Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available.
- Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B. Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. Lipids Health Dis. 2026 Mar 5;25(1):106. doi: 10.1186/s12944-026-02897-3.
- Mach F, Koskinas KC, Roeters van Lennep JE, Tokgozoglu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025 Nov 7;46(42):4359-4378. doi: 10.1093/eurheartj/ehaf190. No abstract available.
- Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- UKC-PCSK9-DUO
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .